{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:52:12Z","timestamp":1771469532517,"version":"3.50.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Systemic sclerosis (SSc) remains a therapeutic challenge, with conventional immunosuppressive strategies showing inconsistent effects and no disease modifying activity. The lack of head-head trials comparing immunosuppressives with emerging antifibrotic agents further complicates treatment decisions in SSc. This review aims to provide an update on the recent advances in targeted therapies for SSc, with a focus on novel biologics and small molecules that specifically modulate key mechanisms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Advances in molecular profiling have revealed inflammatory and fibrotic endotypes within SSc while imaging studies support a fibroinflammatory subset, highlighting potential therapeutic targets.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>A literature search for clinical trials between January 2020 and April 2025 from PubMed\/MEDLINE, clinicaltrials.gov, euclinicaltrials.eu databases for targeted therapies in systemic sclerosis revealed a total of 117 clinical trials, of which we described the design, methods and endpoints from 14 studies (2 conference abstracts, 11 trials and 1 case series). These study results offer hope for patients with systemic sclerosis and pave way for future studies directing the development of patient-specific guidelines.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001121","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T11:00:06Z","timestamp":1755687606000},"page":"392-403","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Targeted therapies in systemic sclerosis: a narrative review of novel drugs in clinical trials"],"prefix":"10.1097","volume":"37","author":[{"given":"Morgan","family":"Emokpae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manvitha","family":"Nadella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"R1-20251007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00281-015-0505-5","article-title":"Vasculopathy in scleroderma","volume":"37","author":"Asano","year":"2015","journal-title":"Semin Immunopathol"},{"key":"R2-20251007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primer"},{"key":"R3-20251007","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","article-title":"Systemic sclerosis and lupus: points in an interferon-mediated continuum","volume":"62","author":"Assassi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R4-20251007","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"R5-20251007","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3390\/cells11060980","article-title":"T cells, interleukin-2 and systemic lupus erythematosus-from pathophysiology to therapy","volume":"11","author":"Mak","year":"2022","journal-title":"Cells"},{"key":"R6-20251007","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R7-20251007","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","article-title":"Emerging targets of disease-modifying therapy for systemic sclerosis","volume":"15","author":"Volkmann","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R8-20251007","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1002\/art.39797","article-title":"An autotaxin-LPA-IL-6 amplification loop drives scleroderma fibrosis","volume":"68","author":"Castelino","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R9-20251007","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-021-02536-5","article-title":"An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years","volume":"23","author":"Campochiaro","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R10-20251007","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.hlc.2018.03.027","article-title":"An introduction to writing narrative and systematic reviews \u2014 tasks, tips and traps for aspiring authors","volume":"27","author":"Gregory","year":"2018","journal-title":"Heart Lung Circ"},{"key":"R11-20251007","doi-asserted-by":"crossref","first-page":"100130","DOI":"10.1016\/j.jtauto.2021.100130","article-title":"Regulatory T cell function in autoimmune disease","volume":"4","author":"Rajendiran","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"R12-20251007","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3389\/fimmu.2018.02356","article-title":"Regulatory T cells in systemic sclerosis","volume":"9","author":"Frantz","year":"2018","journal-title":"Front Immunol"},{"key":"R13-20251007","doi-asserted-by":"crossref","first-page":"e5981","DOI":"10.1371\/journal.pone.0005981","article-title":"Increased Frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) Is Related to a diminished CD69 and TGF\u03b2 EXPRESSION","volume":"4","author":"Radstake","year":"2009","journal-title":"PLoS One"},{"key":"R14-20251007","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cellimm.2009.12.009","article-title":"Regulatory T cells (CD4+CD25brightFoxP3+) expansion in systemic sclerosis correlates with disease activity and severity","volume":"261","author":"Slobodin","year":"2010","journal-title":"Cell Immunol"},{"key":"R15-20251007","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clim.2010.06.004","article-title":"Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis: correlations with disease severity and phenotypes","volume":"137","author":"Giovannetti","year":"2010","journal-title":"Clin Immunol"},{"key":"R16-20251007","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote t-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R17-20251007","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R18-20251007","doi-asserted-by":"crossref","first-page":"e003500","DOI":"10.1136\/rmdopen-2023-003500","article-title":"Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1\u2013phase 2a study","volume":"10","author":"Barde","year":"2024","journal-title":"RMD Open [Internet]"},{"key":"R20-20251007","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/ard.2010.137935","article-title":"The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study","volume":"70","author":"Becker","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R21-20251007","doi-asserted-by":"crossref","first-page":"240015","DOI":"10.1183\/16000617.0015-2024","article-title":"Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis","volume":"33","author":"Volkmann","year":"2024","journal-title":"Eur Respir Rev"},{"key":"R22-20251007","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/art.42477","article-title":"A 24-week, phase IIa, randomized, double-blind, placebo-controlled study of ziritaxestat in early diffuse cutaneous systemic sclerosis","volume":"75","author":"Khanna","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R23-20251007","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-022-02787-w","article-title":"The role of endothelin and RAS\/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications","volume":"24","author":"Rokni","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R24-20251007","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.phrs.2011.01.011","article-title":"The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis","volume":"63","author":"Leask","year":"2011","journal-title":"Pharmacol Res"},{"key":"R25-20251007","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-022-02818-6","article-title":"Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial","volume":"24","author":"Stern","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R27-20251007","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1513\/pats.201201-003AW","article-title":"TGF-\u03b2 activation and lung fibrosis","volume":"9","author":"Tatler","year":"2012","journal-title":"Proc Am Thorac Soc"},{"key":"R28-20251007","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3899\/jrheum.191365","article-title":"STRATUS: a phase II study of abituzumab in patients with systemic sclerosis\u2013associated interstitial lung disease","volume":"48","author":"Khanna","year":"2021","journal-title":"J Rheumatol"},{"key":"R29-20251007","first-page":"1751","article-title":"Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis","volume":"151","author":"Mavalia","year":"1997","journal-title":"Am J Pathol"},{"key":"R30-20251007","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/rheumatology\/keae235","article-title":"Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial","volume":"64","author":"Fern\u00e1ndez-Codina","year":"2025","journal-title":"Rheumatology"},{"key":"R31-20251007","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud's phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"N Engl J Med"},{"key":"R32-20251007","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/annrheumdis-2020-eular.5503","article-title":"SAT0315 inhibition of microsomal prostaglandin e synthase-1 (MPGES-1) by GS-248 Reduces prostaglandin E2 biosynthesis while increasing prostacyclin in human subjects","volume":"79","author":"Edenius","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R33-20251007","doi-asserted-by":"crossref","first-page":"14507","DOI":"10.1073\/pnas.0606586103","article-title":"Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis","volume":"103","author":"Wang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R34-20251007","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/rheumatology\/keae049","article-title":"A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's","volume":"64","author":"Tornling","year":"2024","journal-title":"Rheumatology"},{"key":"R35-20251007","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/ijms26010113","article-title":"Direct vascular effects of angiotensin II (a systematic short review)","volume":"26","author":"N\u00e1dasy","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R36-20251007","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol Rev"},{"key":"R37-20251007","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/keac426","article-title":"A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's","volume":"62","author":"Herrick","year":"2023","journal-title":"Rheumatology"},{"key":"R38-20251007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13075-020-02266-0","article-title":"The role of the oncostatin M\/OSM receptor ( axis in activating dermal microvascular endothelial cells in systemic sclerosis","volume":"22","author":"Marden","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R39-20251007","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/art.40455","article-title":"Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"70","author":"Stifano","year":"2018","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"R40-20251007","doi-asserted-by":"crossref","first-page":"13281","DOI":"10.1038\/s41598-017-13511-z","article-title":"Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis","volume":"7","author":"Ayaub","year":"2017","journal-title":"Sci Rep"},{"key":"R41-20251007","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/rheumatology\/keac300","article-title":"Biological and clinical insights from a randomized phase 2 study of an antioncostatin M monoclonal antibody in systemic sclerosis","volume":"62","author":"Denton","year":"2023","journal-title":"Rheumatology"},{"key":"R42-20251007","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor \u03b2\u2014at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"R43-20251007","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/ijms23073904","article-title":"PDGF\/PDGFR: a possible molecular target in scleroderma fibrosis","volume":"23","author":"Paolini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R44-20251007","doi-asserted-by":"crossref","first-page":"e47160","DOI":"10.1371\/journal.pone.0047160","article-title":"A purpose-synthesised antifibrotic agent attenuates experimental kidney diseases in the rat","volume":"7","author":"Gilbert","year":"2012","journal-title":"PLoS One"},{"key":"R46-20251007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2011.01.013","article-title":"Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis","volume":"139","author":"Fenoglio","year":"2011","journal-title":"Clin Immunol"},{"key":"R47-20251007","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","article-title":"Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism","volume":"111","author":"Zanin-Zhorov","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"R48-20251007","first-page":"103343","article-title":"Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease","volume":"70","author":"Ali","year":"2022","journal-title":"Curr Res Transl Med"},{"key":"R49-20251007","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1093\/rheumatology\/keaf062","article-title":"Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study","volume":"64","author":"Chung","year":"2025","journal-title":"Rheumatol Oxf Engl"},{"key":"R50-20251007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1756-185X.2011.01654.x","article-title":"Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients","volume":"15","author":"Higgs","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"R51-20251007","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/art.30159","article-title":"Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension","volume":"63","author":"Hsu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R52-20251007","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased interleukin-17 production in patients with systemic sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R53-20251007","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.imlet.2017.09.007","article-title":"Is there a role for IL-17 in the pathogenesis of systemic sclerosis?","volume":"195","author":"Chizzolini","year":"2018","journal-title":"Immunol Lett"},{"key":"R54-20251007","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2023.02.061","article-title":"Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a single-arm, open-label, phase 1 trial","volume":"89","author":"Fukasawa","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R55-20251007","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.molimm.2004.06.025","article-title":"Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis","volume":"41","author":"Sato","year":"2004","journal-title":"Mol Immunol"},{"key":"R56-20251007","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R57-20251007","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R58-20251007","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2022-eular.2519","article-title":"POS0881 efficacy and safety of subcutaneous brodalumab, a fully human ANTI-IL-17RA monoclonal antibody, for systemic sclerosis with moderate-to-severe skin thickening: a multicenter, randomized, placebo-controlled, double-blind phase 3 study","volume":"81","author":"Fukasawa","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R60-20251007","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R62-20251007","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:01:10Z","timestamp":1759813270000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001121","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}